Editorial: Therapeutic Drug Monitoring of Infliximab During Induction Therapy in IBD —Is This the Time for Model Informed Precision Dosing?
Alimentary Pharmacology & Therapeutics · 2026-11-04
DOI: 10.1111/apt.71087 ↗At a glance
Editorial in Alimentary Pharmacology & Therapeutics, published online on 2026-11-04. Written by Benjamin Mecsas-Faxon and 2 co-authors. Institution: Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachus…. 28 references.
Abstract (original language)
Intet abstract tilgængeligt.
Authors and institutions
- Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
ORCID profiles: Konstantinos Papamichael, Adam S Cheifetz
Cite
APA
Mecsas-Faxon, B., Papamichael, K., & Cheifetz, A. S. (2026). Editorial: Therapeutic Drug Monitoring of Infliximab During Induction Therapy in IBD —Is This the Time for Model Informed Precision Dosing?. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71087
Vancouver
Mecsas-Faxon B, Papamichael K, Cheifetz AS. Editorial: Therapeutic Drug Monitoring of Infliximab During Induction Therapy in IBD —Is This the Time for Model Informed Precision Dosing?. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71087
BibTeX
@article{MecsasFaxon2026,
author = {Mecsas-Faxon, Benjamin and Papamichael, Konstantinos and Cheifetz, Adam S},
title = {Editorial: Therapeutic Drug Monitoring of Infliximab During Induction Therapy in IBD —Is This the Time for Model Informed Precision Dosing?},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.71087}
}
EUVIMED